Market Research Logo

North America Viral Vector Vaccines Manufacturing Market Forecast 2019-2027

North America Viral Vector Vaccines Manufacturing Market Forecast 2019-2027

KEY FINDINGS

The North American market that manufactures viral vector vaccines is expected to register a CAGR of 18.44% during the forecast period of 2019-2027 . In the field of vaccines, viral vectors have shown promising results in human and veterinary pathogens demanding a broad spectrum immune response from a host to gain control.

MARKET INSIGHTS

Advancements in the gene-editing tools are likely to provide influx to the growth of the market owing to the technical expertise through investments, which is expected to boost the growth of the viral vector vaccine manufacturing market during the forecast period. High government investments in CRISPR research were observed in the U.S. In Canada; the government is actively involved in enhancing research and development activities to cure influenza. Such concerns are likely to increase the need for viral vector vaccines owing to the ongoing research activities to develop. In this report, the overall viral vaccine manufacturing market has been segmented on the basis of types, applications and diseases.

COMPETITIVE INSIGHTS

Leading market players in the North American viral vector vaccine manufacturing market are Ceva Corporate, Batavia Biosciences, Applied Viromics, Janssen Pharmaceutical Inc., Brammer Bio, Id Pharma Co. Ltd., Benitec Biopharma, Advanced Biotherapeutics Consulting, Advanced Bioscience Laboratories Inc., Biogen Idec (Now Biogen Inc.), Biovian, Boehringer Ingelheim Gmbh, Cell And Gene Therapy Catapult, Cobra Biologics (Subsidiary Of Recip Ab) and Ge Healthcare.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Pox Virus Constitutes The Largest Market Share In Terms Of Types
3.2.2. Human Diseases Are Anticipated To Grow Significantly During The Forecast Period
3.2.3. Multivalent Applications Are Widely Used In The Viral Vector Manufacturing Market
4. Market Determinants
4.1. Market Drivers
4.1.1. Promising Results From Several Clinical Studies
4.1.2. Mounting Number Of Viral Vectors Gene-therapy-based Clinical Trials
4.1.3. Growing Chronic Diseases
4.2. Market Opportunities
4.2.1. Swelling Investment In Gene-therapy-based R&D Activities
4.2.2. Increase In The Research And Development
4.3. Market Restraints
4.3.1. Poor Reimbursement System
4.3.2. Stringent Government Policies
4.4. Market Challenges
4.4.1. Unfavourable Compensation Situation
4.4.2. Pricing Pressure Coupled With Lack Of Product Differentiation
4.4.3. Rigorous Regulatory Agenda
5. Market Segmentation
5.1. Market By Types 2019-2027
5.1.1. Adenoviral Vectors
5.1.2. Retroviral Vectors
5.1.3. Lentiviral Vectors
5.1.4. Adeno-associated Viral Vectors
5.1.5. Poxvirus
5.1.6. Cytomegalovirus
5.1.7. Other Viral Vectors
5.2. Market By Application 2019-2027
5.2.1. Multivalent
5.2.2. Multipathogen
5.3. Market By Diseases 2019-2027
5.3.1. Human Diseases
5.3.1.1. Hepatitis
5.3.1.2. Cancer
5.3.1.3. Malaria
5.3.1.4. Tuberculosis
5.3.1.5. Influenza
5.3.1.6. Hiv
5.3.1.7. Other Human Diseases
5.3.2. Veterinary Diseases
5.3.2.1. Avian Influenza
5.3.2.2. Marek's Disease
5.3.2.3. Infectious Bronchitis
5.3.2.4. Ppr Disease
5.3.2.5. Other Veterinary Diseases
6. Key Analytics
6.1. Evolution And Transition
6.2. Regulatory Framework
6.2.1. The United States
6.3. Key Properties Of Viral Vector
6.4. Characteristics Of Potential Viral Vaccine Vectors
6.5. Patent Analysis
6.5.1. The United States Patent Analysis
6.6. Manufacturing Process Of A Viral-vector
6.7. Small-scale Manufacturing Process Of Adenovirus
6.8. Key Suppliers In Viral Vector Market
6.9. Key Buying Criteria
7. Geographical Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada
8. Company Profiles
8.1. Advanced Biotherapeutics Consulting
8.2. Advanced Bioscience Laboratories Inc.
8.3. Applied Viromics
8.4. Batavia Biosciences
8.5. Benitec Biopharma
8.6. Biogen Idec (Now Biogen Inc.)
8.7. Biovian
8.8. Brammer Bio
8.9. Boehringer Ingelheim Gmbh
8.10. Cell And Gene Therapy Catapult
8.11. Ceva Corporate
8.12. Cobra Biologics (Subsidiary Of Recip Ab)
8.13. Ge Healthcare
8.14. Janssen Pharmaceutical Inc.
8.15. Id Pharma Co. Ltd.
Table List
Table 1 North America Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousand)
Table 2 Ongoing Clinical Trials Related To Viral Vectors
Table 3 Various Viral Vectors Properties And Their Application In Gene Therapy
Table 4 North America Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 5 Key Viral Vectors Characteristics
Table 6 North America Viral Vector Vaccine Manufacturing Market In Adenoviral Vectors 2019-2027 ($ Thousands)
Table 7 North America Viral Vector Vaccine Manufacturing Market In Retroviral Vectors 2019-2027 ($ Thousands)
Table 8 Advantages And Disadvantages Of Retroviral Vectors
Table 9 Components Of Hiv Provirus
Table 10 North America Viral Vector Vaccine Manufacturing Market In Lentiviral Vectors 2019-2027 ($ Thousands)
Table 11 Second- Vs. Third-generation Lentiviral Systems
Table 12 Aav Vectors With Their Tropisms And Receptors
Table 13 North America Viral Vector Vaccine Manufacturing Market In Adeno-associated Viral Vectors 2019-2027 ($ Thousands)
Table 14 Licensed Fowl Pox Viral-vectored Veterinary Vaccines
Table 15 North America Viral Vector Vaccine Manufacturing Market In Pox Virus 2019-2027 ($ Thousands)
Table 16 North America Viral Vector Vaccine Manufacturing Market In Cytomegalovirus 2019-2027 ($ Thousands)
Table 17 North America Viral Vector Vaccine Manufacturing Market In Other Viral Vectors 2019-2027 ($ Thousands)
Table 18 North America Viral Vector Vaccine Manufacturing Market By Application 2019-2027 ($ Thousands)
Table 19 North America Viral Vector Vaccine Manufacturing Market In Multivalent 2019-2027 ($ Thousands)
Table 20 Tb Statistics For 2016
Table 21 North America Viral Vector Vaccine Manufacturing Market In Multipathogen 2019-2027 ($ Thousands)
Table 22 North America Viral Vector Vaccine Manufacturing Market By Diseases 2019-2027 ($ Thousands)
Table 23 North America Viral Vector Vaccine Manufacturing Market In Human Diseases 2019-2027 ($ Thousands)
Table 24 North America Viral Vector Vaccine Manufacturing Market In Human Diseases By Types 2019-2027 ($ Thousands)
Table 25 North America Human Diseases Market In Hepatitis 2019-2027 ($ Thousands)
Table 26 Estimated Actual New Cases Of Hav
Table 27 North America Human Diseases Market In Cancer 2019-2027 ($ Thousands)
Table 28 Estimated New Cancer Cases In The United States 2017
Table 29 North America Human Diseases Market In Malaria 2019-2027 ($ Thousands)
Table 30 Malaria Vaccine Development Initiatives
Table 31 Viral Vector Vaccine Candidates For Tuberculosis
Table 32 North America Human Diseases Market In Tuberculosis 2019-2027 ($ Thousands)
Table 33 North America Human Diseases Market In Influenza 2019-2027 ($ Thousands)
Table 34 Benefits And Concern For Virus-vectored Experimental Influenza Vaccines
Table 35 North America Human Diseases Market In Hiv 2019-2027 ($ Thousands)
Table 36 North America Human Diseases Market In Other Human Diseases 2019-2027 ($ Thousands)
Table 37 Ongoing Clinical Trials And Development In Zika Virus Vaccine
Table 38 Licensed Viral-vectored Veterinary Vaccines
Table 39 North America Viral Vector Vaccine Manufacturing Market In Veterinary Diseases 2019-2027 ($ Thousands)
Table 40 North America Viral Vector Vaccine Manufacturing Market In Veterinary Diseases By Types 2019-2027 ($ Thousands)
Table 41 Avian Influenza Vaccines
Table 42 North America Veterinary Diseases Market In Avian Influenza 2019-2027 ($ Thousands)
Table 43 North America Veterinary Diseases Market In Marek's Disease 2019-2027 ($ Thousands)
Table 44 Marek’s Disease Vaccines
Table 45 North America Veterinary Diseases Market In Infectious Bronchitis 2019-2027 ($ Thousands)
Table 46 North America Veterinary Diseases Market In Ppr Disease 2019-2027 ($ Thousands)
Table 47 North America Veterinary Diseases Market In Other Veterinary Diseases 2019-2027 ($ Thousands)
Table 48 North America Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Table 49 North America Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Table 50 Funding In Cancer Research In The United States ($ Millions)
Table 51 The United States Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Table 52 Nih Funding For Crispr-related Research 2006-2016 ($)
Table 53 Canada Viral Vector Vaccine Manufacturing Market By Types 2019-2027 ($ Thousands)
Figures List
Figure 1 North America Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousand)
Figure 2 Schematic Overview Of Multivalent And Multipathogen Viral Vector Vaccines
Figure 3 Estimation Of People Living With Hiv 2016 (Million)
Figure 4 Prevalence Of Hbv Infection In The General Population 2015 (Millions)
Figure 5 Vaccine Advancements Timeline
Figure 6 Steps Requirement For Vaccine Approval
Figure 7 Vaccine Review And Regulation Steps Under Fda
Figure 8 Manufacturing Process Of Adenovirus
Figure 9 The United States Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)
Figure 10 Canada Viral Vector Vaccine Manufacturing Market 2019-2027 ($ Thousands)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report